1986
DOI: 10.1016/0091-6749(86)90114-4
|View full text |Cite
|
Sign up to set email alerts
|

Spontaneous histamine release after exposure to hyperosmolar solutions

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
8
0

Year Published

1986
1986
2011
2011

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 27 publications
(8 citation statements)
references
References 29 publications
0
8
0
Order By: Relevance
“…Considering that b 2 -agonists may affect the degranulation of inflammatory cells, as demonstrated by in vitro and in vivo studies [31,32], it was thought that this effect might mask a possible difference between HS and IS solution mediator release. Since in vitro studies have demonstrated that HS solution can activate inflammatory cells [6][7][8][9], and there is no demonstration from in vivo studies that MPO, EPX and NE levels are similar in HS-and ISinduced sputum supernatant [4], b 2 -agonist pretreatment was avoided in the present comparison between HS-and ISinduced sputum. However, this fact is not relevant in practice, because guidelines recommend b 2 -pretreatment before both HS and IS inhalation [1].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Considering that b 2 -agonists may affect the degranulation of inflammatory cells, as demonstrated by in vitro and in vivo studies [31,32], it was thought that this effect might mask a possible difference between HS and IS solution mediator release. Since in vitro studies have demonstrated that HS solution can activate inflammatory cells [6][7][8][9], and there is no demonstration from in vivo studies that MPO, EPX and NE levels are similar in HS-and ISinduced sputum supernatant [4], b 2 -agonist pretreatment was avoided in the present comparison between HS-and ISinduced sputum. However, this fact is not relevant in practice, because guidelines recommend b 2 -pretreatment before both HS and IS inhalation [1].…”
Section: Discussionmentioning
confidence: 99%
“…A large number of in vivo and in vitro studies have shown that hypertonic solutions modify mediator release from inflammatory cells by acting as a strong stimulus for cell activation [6][7][8], or, conversely, by inhibiting leukocyte degranulation [5,9]. In sputum induction, the hypertonic solution might increase osmolarity of the airway lining fluid, thus influencing mediator release from granulocytes during inhalation or sputum processing, or both.…”
mentioning
confidence: 99%
“…This results in the release of pre‐formed granule‐derived mediators and neutral proteases, the synthesis and release of newly formed lipid products and the transcription of numerous cytokines [28–32] (Table 1). In addition to this conventional IgE‐dependent mast cell activation, recent studies indicate that some allergens such as Der p 1, which is a serine protease, as well as neuropeptides, eosinphil products, defensins and changes in osmolality can induce mast cell histamine and cytokine secretion directly through IgE‐ independent mechanisms [33–37].…”
Section: Mast Cell Biologymentioning
confidence: 99%
“…There was no basophil activation following negative control stimulation (stimulation buffer), but similar responses to positive stimulation controls (anti-FcεRI) and (fMLP), suggesting basophil hyper-releaseability was specific to basophils from food allergic subjects as has been reported previously. (3235) Vonakis et al (28) demonstrated that cultured peripheral blood basophils from chronic idiopathic urticaria patients spontaneously degranulated, and that basophils from responders among these patients contained significantly increased splenocytes tyrosine kinase (Syk) and decreased SHIP-2 as compared to non responders and normals. In addition, Kepley et al (36) detected less Syk in basophils of nonresponders.…”
Section: Discussionmentioning
confidence: 99%